All Updates

All Updates

icon
Filter
Product updates
PathAI launches PathExplore, an AI-powered pathology tool
AI Drug Discovery
Apr 4, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Apr 4, 2023

PathAI launches PathExplore, an AI-powered pathology tool

Product updates

  • AI-powered bioinformatics company PathAI has launched PathExplore, which the company claims is the world’s first AI-powered pathology tool that provides standardized and scalable panel of human interpretable features (HIFs) for analyzing the tumor microenvironment (TME) with deep resolution. It provides oncology drug developers with high resolution of the TME, enabling researchers to unlock insights that will inform the next phase of targeted oncology drug development.

  • PathExplore generates a panel of over 600 quantitative HIFs to analyze the TME with single-cell resolution, producing overlay visualizations of cell types and tissue regions that are accessible on PathAI's AISight Translational Research platform. The AI-powered tool has been trained using more than 6.5 million annotations by pathologists on 66,000 slides. Currently, PathExplore is available for eight cancers, including breast cancer, colorectal cancer, non-small cell lung cancer and pancreatic cancer, with more planned to launch later this year. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.